Optimer Pharmaceuticals Announces Oral Presentation at Digestive Disease Week (DDW) Featuring Data From the Second Fidaxomicin Phase 3 Trial
SAN DIEGO, April 22 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data from the second fidaxomicin Phase 3 clinical study will be presented in an oral presentation at Digestive Disease Week (DDW) 2010 in New Orleans.
"Randomized Clinical Trial (RCT) in Clostridium difficile Infection (CDI) Confirms Superiority of Fidaxomicin over Vancomycin" |
|
Oral Presentation by: Stuart Johnson, M.D. |
|
Tuesday, May 4, 2010 2:15pm-3:45pm Central Daylight Time |
|
Abstract number: 828630 |
|
Location: Ballroom C, Ernest N. Morial Convention Center |
|
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection. Optmer has reported positive top-line results from two Phase 3 trials of fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Optimer has also successfully completed two Phase 3 trials with Pruvel. Additional information can be found at http://www.optimerpharma.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
Contacts |
|
Optimer Pharmaceuticals, Inc. |
|
Christina Donaghy, Corporate Communications Manager |
|
John D. Prunty, Chief Financial Officer & VP Finance |
|
858-909-0736 |
|
Porter Novelli Life Sciences |
|
Jason I. Spark, Vice President |
|
619-849-6005 |
|
SOURCE Optimer Pharmaceuticals, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article